Longitude Prize on ALS
The MND Association has committed to a partnership with Challenge Works to support the Longitude Prize on ALS. The £7.5million Challenge Prize aims to incentivise the use of AI-based approaches to transform drug discovery for the treatment of amyotrophic lateral sclerosis (ALS), the most common form of MND.
We’re proud to be the principal funder for the Prize, which is seeking entries from innovators from across medical research, biotech, techbio, pharmaceuticals and AI.
There are many different approaches to drug discovery and development, and as the biggest charity funder of MND research in the UK, it's important that we're working on a number of fronts to maximise our chances of finding effective treatments for MND.
The Longitude Prize on ALS is exciting for a number of reasons – the international scope of the prize, the prospect of new talented people getting involved in MND research for the first time and bringing together existing MND data from different sources across the world to increase the chance of finding something transformative for the MND community. We are proud to be the principal funder of this innovative prize.
Dr Mike Rogers, Director of Research and Innovation at the MND Association
Entries
Open for entries until 3 December 2025, it will initially award 20 teams £100,000 each in early 2026, with one team going on to win £1 million at the end of the five year Prize.
Challenge prizes create a level playing field for innovators regardless of previous expertise, enabling the most promising ideas to progress with funding and expert support.
Listen to our podcast discussing the Longitude Prize on ALS
